SXTC

MKT CAP:$2M

China SXT Pharmaceuticals, Inc.

Market Cap

$2M

Healthcare·Drug Manufacturers - Specialty & Generic·🇨🇳 China·NASDAQ

Healthcare·Drug·🇨🇳·NASDAQ

Stock Price

$2.02-$259.13 (-99.23%)

Apr 21, 2026

Company Details

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP pr...

CEO

Feng Zhou

IPO Date

Jan 4, 2019

Website

www.sxtchina.com

Key Metrics TTM

Revenue

$2M

-5.4% YoY

Net Income

-$3M

EPS (Diluted)

-$3.00

Free Cash Flow

-$2M

Revenue / Share

$0.71

Gross Margin

21.1%

Operating Margin

-154.0%

Net Margin

-189.8%

FCF Margin

-134.8%

P/S

0.9x

P/E

—

Earnings Reports

FY 2025

Jul 31, 2025

$2M-9.7%EPS -$8.18

Q4 2025

Jul 31, 2025

$455.7K-7.8%EPS -$0.51

Q3 2025

Dec 31, 2024

$455.7K-7.8%EPS -$0.51

Q2 2025

Mar 28, 2025

$414.7KEPS -$0.99

Q1 2025

Jun 30, 2024

$414.7K-11.7%EPS -$0.99

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 20	$973.6K	$432.2K	-$560.2K
Q1 21	$2M	$1M	-$4M
Q2 21	$2M	$1M	-$4M
Q3 21	$458.5K	$9.3K	-$6M
Q1 22	$513.8K	$162.0K	-$1M
Q2 22	$513.8K	$324.0K	-$1M
Q3 22	$787.3K	$463.8K	-$1M
Q1 23	$604.1K	$44.8K	-$575.2K
Q3 23	$381.7K	$168.3K	-$2M
Q1 24	$469.8K	$144.2K	-$5M
Q3 24	$494.5K	$132.8K	$3M
Q4 24	$494.5K	$132.8K	$3M
Q1 25	$414.7K	$67.4K	-$319.1K
Q2 25	$414.7K	$67.4K	-$319.1K
Q3 25	$455.7K	$116.3K	-$1M
Q4 25	$455.7K	$116.3K	-$1M

Valuation

Quarter	P/S	P/E
Q3 20	0.3x	—
Q1 21	0.3x	—
Q2 21	0.3x	—
Q3 21	0.3x	—
Q1 22	0.3x	—
Q2 22	0.5x	—
Q3 22	0.7x	—
Q1 23	0.7x	—
Q3 23	0.7x	—
Q1 24	0.7x	—
Q3 24	0.8x	—
Q4 24	0.9x	—
Q1 25	0.9x	1.2x
Q2 25	0.9x	0.3x
Q3 25	0.9x	1.3x
Q4 25	0.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 20	$1M	$1M
Q1 21	-$166.8K	-$226.4K
Q2 21	-$333.5K	-$452.7K
Q3 21	-$491.5K	-$478.4K
Q1 22	-$156.2K	-$166.7K
Q2 22	-$312.3K	-$333.5K
Q3 22	$290.3K	$269.6K
Q1 23	-$274.6K	-$284.6K
Q3 23	$234.2K	$208.9K
Q1 24	-$289.8K	-$289.8K
Q3 24	-$674.2K	-$677.8K
Q4 24	-$674.2K	-$677.8K
Q1 25	-$678.6K	-$678.6K
Q2 25	-$678.6K	-$678.6K
Q3 25	-$494.1K	-$495.1K
Q4 25	-$494.1K	-$495.1K

Capital Expenditures

Quarter	CapEx
Q3 20	$16.5K
Q1 21	$59.6K
Q2 21	$119.2K
Q3 21	$13.1K
Q1 22	$10.6K
Q2 22	$21.1K
Q3 22	$20.7K
Q1 23	$10.1K
Q3 23	$25.3K
Q1 24	$0
Q3 24	$3.5K
Q4 24	$3.5K
Q1 25	$0
Q2 25	$0
Q3 25	$1.0K
Q4 25	$1.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 20	-32.0%	+35.4%
Q1 21	-1.5%	+320.5%
Q2 21	+24.8%	+310.8%
Q3 21	-71.5%	+263.1%
Q1 22	-47.2%	+27.8%
Q2 22	-73.4%	-64.0%
Q3 22	-59.2%	-64.5%
Q1 23	+31.8%	-81.1%
Q3 23	-25.7%	+33.2%
Q1 24	-8.6%	+162.5%
Q3 24	-37.2%	-250.9%
Q4 24	-18.2%	-347.8%
Q1 25	+8.7%	-71.9%
Q2 25	-11.7%	-85.7%
Q3 25	-7.8%	+150.5%
Q4 25	-7.8%	+150.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 20	$0	0.0%
Q1 21	$0	0.0%
Q2 21	$0	0.0%
Q3 21	$0	0.0%
Q1 22	$162.9K	31.7%
Q2 22	$162.9K	31.7%
Q3 22	$1M	127.6%
Q1 23	$138.6K	22.9%
Q3 23	$138.6K	36.3%
Q1 24	$0	0.0%
Q3 24	$176.1K	35.6%
Q4 24	$176.1K	35.6%
Q1 25	$0	0.0%
Q2 25	$0	0.0%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	G&A	S&M
Q3 20	$587.8K	$404.5K
Q1 21	$476.3K	$352.3K
Q2 21	$828.6K	—
Q3 21	$1M	$441.4K
Q1 22	$1M	$198.4K
Q2 22	$1M	$198.4K
Q3 22	$1M	$263.9K
Q1 23	$484.0K	$136.1K
Q3 23	$2M	$57.6K
Q1 24	$5M	$88.5K
Q3 24	$4M	$128.3K
Q4 24	$4M	$128.3K
Q1 25	$361.2K	$25.3K
Q2 25	$361.2K	$25.3K
Q3 25	$1M	$119.6K
Q4 25	$1M	$119.6K

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$31.3K	$0	$31.3K
Q3 22	$16M	$0	$16M
Q4 22	$16M	$0	$16M
Q1 23	$3M	$0	$3M
Q2 23	$3M	$0	$3M
Q3 23	$17M	$0	$17M
Q4 23	$17M	$0	$17M
Q1 24	$11M	$0	$11M
Q2 24	$11M	$0	$11M
Q3 24	$12M	$0	$12M
Q4 24	$12M	$0	$12M
Q1 25	$19M	$0	$19M
Q2 25	$19M	$0	$19M
Q3 25	$18M	$137.8K	$18M
Q4 25	$18M	$137.8K	$18M
Q2 26	$21M	$0	$21M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 20	13K	+17.6%	+786.9%
Q1 21	29K	+115.3%	—
Q2 21	29K	0.0%	+172.3%
Q3 21	29K	+0.0%	+153.3%
Q1 22	31K	+8.0%	+132.7%
Q2 22	31K	0.0%	+8.1%
Q3 22	52K	+67.5%	+81.0%
Q1 23	102K	+96.4%	+255.5%
Q3 23	432K	+321.9%	+1287.9%
Q1 24	501K	+16.2%	+1512.5%
Q3 24	867K	+73.0%	+1565.5%
Q4 24	1M	+42.2%	+1105.5%
Q1 25	404K	-67.3%	-6.4%
Q2 25	404K	0.0%	-19.5%
Q3 25	2M	+504.7%	+181.6%
Q4 25	2M	0.0%	+98.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 20	$10.1K	96
Q1 21	$19.9K	97
Q2 21	$19.9K	97
Q3 21	$4.7K	97
Q1 22	$5.4K	96
Q2 22	$5.4K	96
Q3 22	$8.2K	96
Q1 23	$6.9K	88
Q3 23	$4.3K	88
Q1 24	$6.0K	78
Q3 24	$6.3K	78
Q4 24	$6.6K	75
Q1 25	$5.5K	75
Q2 25	$5.5K	75
Q3 25	$6.1K	75
Q4 25	$6.1K	75

Revenue / Employee